These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
326 related items for PubMed ID: 18429687
1. Case report: the danger of postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous testicular carcinoma. Spermon JR, Witjes JA. J Endourol; 2008 May; 22(5):1013-6. PubMed ID: 18429687 [Abstract] [Full Text] [Related]
5. [Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND)]. Nicolai N, Necchi A, Piva L, Stagni S, Catanzaro MA, Biasoni D, Milani A, Torelli T, Salvioni R. Urologia; 2010 May; 77(2):84-7. PubMed ID: 20890864 [Abstract] [Full Text] [Related]
6. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. J Urol; 2012 Feb; 187(2):487-92. PubMed ID: 22177913 [Abstract] [Full Text] [Related]
7. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A. Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267 [Abstract] [Full Text] [Related]
8. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis. Tong S, Chen M, Zu X, Li Y, He W, Lei Y, Liu W, Qi L. Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573 [Abstract] [Full Text] [Related]
13. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003]. Pizzocaro G, Schiavo M, Solima S, Vitellaro M, Biasoni N, Nicolai N. Urologia; 2010 Jun; 77 Suppl 17():50-6. PubMed ID: 21308676 [Abstract] [Full Text] [Related]
14. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study. Dusaud M, Malavaud B, Bayoud Y, Sebe P, Hoepffner JL, Salomon L, Houlgatte A, Pignot G, Rigaud J, Fléchon A, Pfister C, Rouprêt M, Soulié M, Méjean A, Durand X. J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263 [Abstract] [Full Text] [Related]
15. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ. Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550 [Abstract] [Full Text] [Related]
16. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors. Nakamura T, Kawauchi A, Oishi M, Ueda T, Shiraishi T, Nakanishi H, Kamoi K, Naya Y, Hongo F, Okihara K, Miki T. Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172 [Abstract] [Full Text] [Related]